Skip to main content

Table 1 Demographics and clinical characteristics of patients in the primary and validation cohort

From: Development and validation of a risk prediction score for patients with nasopharyngeal carcinoma

Characteristic Primary cohort Validation cohort
n = (363)
No. (%) or
Mean ± sd
n = (156)
No. (%) or
Mean ± sd
Gender
 Male 209 (57.57%) 92 (58.97%)
 Female 154 (42.43%) 64 (41.03%)
Age (years) 46.05 ± 10.87 46.87 ± 11.58
Smoking
 No 277 (76.31%) 123 (78.85%)
 Yes 86 (23.69%) 33 (21.15%)
Family history
 Yes 87 (23.97%) 50 (32.05%)
 No 276 (76.03%) 106 (77.95%)
BMI (kg/m2) 23.17 ± 6.74 22.96 ± 3.37
TNM stagea
 I 11 (3.03%) 6 (3.85%)
 II 47 (12.95%) 22 (14.10%)
 III 179 (49.31%) 69 (44.23%)
 IV 126 (34.71%) 59 (37.82%)
Treatment
 Radiotherapy 300 (82.64%) 129 (82.69%)
 Chemotherapy 63 (17.36%) 27 (17.31%)
WBC (109/L) 7.03 ± 3.33 7.04 ± 3.32
Neutrophils (109/L) 4.55 ± 2.87 4.35 ± 2.25
Lymphocyte (109/L) 1.71 ± 0.73 1.65 ± 0.81
Monocyte (109/L) 0.47 ± 0.24 0.43 ± 1.20
Platelet (109/L) 225.02 ± 69.18 214 ± 67.46
HGB (g/L) 136.63 ± 15.84 137.38 ± 15.62
NLR 3.33 ± 3.82 3.34 ± 2.87
dNLR 2.30 ± 2.28 2.48 ± 4.13
LMR 4.67 ± 4.59 4.58 ± 3.49
PLR 157.39 ± 89.41 156.89 ± 86.88
SII 757.39 ± 822.18 719.40 ± 692.30
TP (g/L) 73.28 ± 5.89 75.56 ± 5.24
ALB (g/L) 43.40 ± 3.29 43.17 ± 3.23
GLOB (g/L) 29.88 ± 4.67 29.39 ± 4.50
AGR 1.49 ± 0.24 1.50 ± 0.26
CRP (mg/L) 4.69 ± 9.93 5.42 ± 9.81
CAR 0.11 ± 0.26 0.13 ± 0.27
APOA (g/L) 1.31 ± 0.25 1.32 ± 0.27
APOB (g/L) 0.99 ± 0.24 0.98 ± 0.25
ABR 1.40 ± 0.42 1.42 ± 0.47
LDH (U/L) 174.47 ± 54.26 176.76 ± 119.25
HDL (U/L) 1.23 ± 0.31 1.221 ± 0.31
EBV DNA (copy/mL)
 < 103 167 (48.8%) 72 (40.5%)
 103–9999 77 (20.8%) 31 (20.8%)
 104–99,999 66 (16.8%) 31 (22.5%)
 105–999,999 36 (8.4%) 10 (9.8%)
 ≥ 106 17 (5.2%) 12 (6.4%)
VCA-IgA
 < 1:80 59 (17.1%) 28 (16.2%)
 1:80–1:320 221 (60.1%) 93 (61.3%)
 ≥ 1:640 83 (22.8%) 35 (22.5%)
EA-IgA
 < 1:10 111 (30.6%) 51 (28.3%)
 1:10–1:20 121 (33.3%) 49 (34.7%)
 ≥ 1:40 131 (36.1%) 56 (37.0%)
PNI 51.94 ± 5.09 51.4 ± 5.17
PI
 0 297 (81.82%) 119 (76.28%)
 1 59 (16.25%) 35 (22.44%)
 2 7 (1.93%) 2 (1.28%)
  1. aTNM stage was classified according to the AJCC 8th TNM staging system
  2. BMI: body mass index; TNM: Tumor Node Metastasis stage; WBC: white blood cell; HGB: hemoglobin; NLR: neutrophil/lymphocyte ratio; dNLR: neutrophil/WBC-neutrophil ratio; LMR: lymphocyte/monocyte ratio; PLR: platelet/lymphocyte ratio; SII: systemic immune-inflammation index; TP: total protein; ALB: albumin; GLOB: globulin; AGR: ALB/GLOB ratio; CRP: C-reactive protein; CAR: C-reactive protein/albumin ratio; APOA: apolipoprotein AI; APOB: apolipoprotein B; ABR: APOA/APOB ratio; LDH: lactic dehydrogenase; HDL: high density lipoprotein; EBV: Epstein-Barr virus; VCA-IgA: viral capsid antigen specific immunoglobulin A; EA-IgA: early antigen immunoglobulin A; PNI: prognostic nutritional index; PI: prognostic index